Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]M. E. Schwab and D. Bartholdi: Degeneration and regeneration of axons in the lesioned spinal cord. Physiol Rev, 76(2), 319-370 (1996)

  • [2]M. G. Fehlings and D. H. Nguyen: Immunoglobulin G: a potential treatment to attenuate neuroinflammation following spinal cord injury. J Clin Immunol, 30 Suppl 1, S109-112 (2010)

  • [3]A. I. Faden and R. P. Simon: A potential role for excitotoxins in the pathophysiology of spinal cord injury. Ann Neurol, 23(6), 623-626 (1988)

  • [4]D. J. McAdoo, G. Y. Xu, G. Robak and M. G. Hughes: Changes in amino acid concentrations over time and space around an impact injury and their diffusion through the rat spinal cord. Exp Neurol, 159(2), 538-544 (1999)

  • [5]P. K. Stys, S. G. Waxman and B. R. Ransom: Ionic mechanisms of anoxic injury in mammalian CNS white matter: role of Na+ channels and Na(+)-Ca2+ exchanger. J Neurosci, 12(2), 430-439 (1992)

  • [6]Y. Xiong, Q. Gu, P. L. Peterson, J. P. Muizelaar and C. P. Lee: Mitochondrial dysfunction and calcium perturbation induced by traumatic brain injury. J Neurotrauma, 14(1), 23-34 (1997)

  • [7]Y. Xiong, P. L. Peterson, B. H. Verweij, F. C. Vinas, J. P. Muizelaar and C. P. Lee: Mitochondrial dysfunction after experimental traumatic brain injury: combined efficacy of SNX-111 and U-101033E. J Neurotrauma, 15(7), 531-544 (1998)

  • [8]E. D. Hall and J. E. Springer: Neuroprotection and acute spinal cord injury: a reappraisal. NeuroRx, 1(1), 80-100 (2004)

  • [9]Y. Xiong, A. G. Rabchevsky and E. D. Hall: Role of peroxynitrite in secondary oxidative damage after spinal cord injury. J Neurochem, 100(3), 639-649 (2007)

  • [10]J. D. Guest, E. D. Hiester and R. P. Bunge: Demyelination and Schwann cell responses adjacent to injury epicenter cavities following chronic human spinal cord injury. Exp Neurol, 192(2), 384-393 (2005)

  • [11]R. J. Dumont, D. O. Okonkwo, S. Verma, R. J. Hurlbert, P. T. Boulos, D. B. Ellegala and A. S. Dumont: Acute spinal cord injury, part I: pathophysiologic mechanisms. Clin Neuropharmacol, 24(5), 254-264 (2001)

  • [12]E. Emery, P. Aldana, M. B. Bunge, W. Puckett, A. Srinivasan, R. W. Keane, J. Bethea and A. D. Levi: Apoptosis after traumatic human spinal cord injury. J Neurosurg, 89(6), 911-920 (1998)

  • [13]I. Koyanagi, C. H. Tator and P. J. Lea: Three-dimensional analysis of the vascular system in the rat spinal cord with scanning electron microscopy of vascular corrosion casts. Part 1: Normal spinal cord. Neurosurgery, 33(2), 277-283; discussion 283-274 (1993)277-283; discussion 283-274 (1993)

  • [14]D. Blond, S. J. Campbell, A. G. Butchart, V. H. Perry and D. C. Anthony: Differential induction of interleukin-1beta and tumour necrosis factor-alpha may account for specific patterns of leukocyte recruitment in the brain. Brain Res, 958(1), 89-99 (2002)

  • [15]L. Fan, P. R. Young, F. C. Barone, G. Z. Feuerstein, D. H. Smith and T. K. McIntosh: Experimental brain injury induces expression of interleukin-1 beta mRNA in the rat brain. Brain Res Mol Brain Res, 30(1), 125-130 (1995)

  • [16]T. Liu, R. K. Clark, P. C. McDonnell, P. R. Young, R. F. White, F. C. Barone and G. Z. Feuerstein: Tumor necrosis factor-alpha expression in ischemic neurons. Stroke, 25(7), 1481-1488 (1994)

  • [17]Y. S. Gwak, J. Kang, G. C. Unabia and C. E. Hulsebosch: Spatial and temporal activation of spinal glial cells: role of gliopathy in central neuropathic pain following spinal cord injury in rats. Exp Neurol, 234(2), 362-372 (2012)

  • [18]J. K. Olson: Immune response by microglia in the spinal cord. Ann N Y Acad Sci, 1198, 271-278 (2010)

  • [19]L. Schnell, S. Fearn, H. Klassen, M. E. Schwab and V. H. Perry: Acute inflammatory responses to mechanical lesions in the CNS: differences between brain and spinal cord. Eur J Neurosci, 11(10), 3648-3658 (1999)

  • [20]L. Schnell, S. Fearn, M. E. Schwab, V. H. Perry and D. C. Anthony: Cytokine-induced acute inflammation in the brain and spinal cord. J Neuropathol Exp Neurol, 58(3), 245-254 (1999)

  • [21]A. di Penta, B. Moreno, S. Reix, B. Fernandez-Diez, M. Villanueva, O. Errea, N. Escala, K. Vandenbroeck, J. X. Comella and P. Villoslada: Oxidative stress and proinflammatory cytokines contribute to demyelination and axonal damage in a cerebellar culture model of neuroinflammation. PLoS One, 8(2), e54722 (2013)

  • [22]I. Dusart and M. E. Schwab: Secondary cell death and the inflammatory reaction after dorsal hemisection of the rat spinal cord. Eur J Neurosci, 6(5), 712-724 (1994)

  • [23]C. A. Oyinbo: Secondary injury mechanisms in traumatic spinal cord injury: a nugget of this multiply cascade. Acta Neurobiologiae Experimentalis, 71(2), 281-299 (2011)

  • [24]M. E. Schwab and L. Schnell: Region-specific appearance of myelin constituents in the developing rat spinal cord. J Neurocytol, 18(2), 161-169 (1989)

  • [25]L. Schnell and M. E. Schwab: Axonal regeneration in the rat spinal cord produced by an antibody against myelin-associated neurite growth inhibitors. Nature, 343 (6255), 269-272 (1990)

  • [26]M. S. Chen, A. B. Huber, M. E. van der Haar, M. Frank, L. Schnell, A. A. Spillmann, F. Christ and M. E. Schwab: Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature, 403 (6768), 434-439 (2000)

  • [27]A. E. Fournier, T. GrandPre and S. M. Strittmatter: Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration. Nature, 409 (6818), 341-346 (2001)

  • [28]W. A. Barton, B. P. Liu, D. Tzvetkova, P. D. Jeffrey, A. E. Fournier, D. Sah, R. Cate, S. M. Strittmatter and D. B. Nikolov: Structure and axon outgrowth inhibitor binding of the Nogo-66 receptor and related proteins. EMBO J, 22(13), 3291-3302 (2003)

  • [29]W. B. Cafferty, P. Duffy, E. Huebner and S. M. Strittmatter: MAG and OMgp synergize with Nogo-A to restrict axonal growth and neurological recovery after spinal cord trauma. J Neurosci, 30(20), 6825-6837 (2010)

  • [30]M. Li, A. Shibata, C. Li, P. E. Braun, L. McKerracher, J. Roder, S. B. Kater and S. David: Myelin-associated glycoprotein inhibits neurite/axon growth and causes growth cone collapse. J Neurosci Res, 46(4), 404-414 (1996)

  • [31]M. E. De Bellard and M. T. Filbin: Myelin-associated glycoprotein, MAG, selectively binds several neuronal proteins. J Neurosci Res, 56(2), 213-218 (1999)

  • [32]D. Hunt, R. S. Coffin and P. N. Anderson: The Nogo receptor, its ligands and axonal regeneration in the spinal cord; a review. J Neurocytol, 31(2), 93-120 (2002)

  • [33]T. Kubo, K. Hata, A. Yamaguchi and T. Yamashita: Rho-ROCK inhibitors as emerging strategies to promote nerve regeneration. Curr Pharm Des, 13(24), 2493-2499 (2007)

  • [34]K. T. Baldwin and R. J. Giger: Insights into the physiological role of CNS regeneration inhibitors. Front Mol Neurosci, 8, 23 (2015)

  • [35]J. K. Lee, C. G. Geoffroy, A. F. Chan, K. E. Tolentino, M. J. Crawford, M. A. Leal, B. Kang and B. Zheng: Assessing spinal axon regeneration and sprouting in Nogo-, MAG-, and OMgp-deficient mice. Neuron, 66(5), 663-670 (2010)

  • [36]A. E. Fournier, B. T. Takizawa and S. M. Strittmatter: Rho kinase inhibition enhances axonal regeneration in the injured CNS. J Neurosci, 23(4), 1416-1423 (2003)

  • [37]R. J. Gilbert, R. J. McKeon, A. Darr, A. Calabro, V. C. Hascall and R. V. Bellamkonda: CS-4,6 is differentially upregulated in glial scar and is a potent inhibitor of neurite extension. Mol Cell Neurosci, 29(4), 545-558 (2005)

  • [38]H. Wang, Y. Katagiri, T. E. McCann, E. Unsworth, P. Goldsmith, Z. X. Yu, F. Tan, L. Santiago, E. M. Mills, Y. Wang, A. J. Symes and H. M. Geller: Chondroitin-4-sulfation negatively regulates axonal guidance and growth. J Cell Sci, 121(Pt 18), 3083-3091 (2008)

  • [39]S. Karimi-Abdolrezaee and R. Billakanti: Reactive astrogliosis after spinal cord injury-beneficial and detrimental effects. Mol Neurobiol, 46(2), 251-264 (2012)

  • [40]R. J. McKeon, R. C. Schreiber, J. S. Rudge and J. Silver: Reduction of neurite outgrowth in a model of glial scarring following CNS injury is correlated with the expression of inhibitory molecules on reactive astrocytes. J Neurosci, 11(11), 3398-3411 (1991)

  • [41]F. M. Maynard, Jr., M. B. Bracken, G. Creasey, J. F. Ditunno, Jr., W. H. Donovan, T. B. Ducker, S. L. Garber, R. J. Marino, S. L. Stover, C. H. Tator, R. L. Waters, J. E. Wilberger and W. Young: International Standards for Neurological and Functional Classification of Spinal Cord Injury. American Spinal Injury Association. Spinal Cord, 35(5), 266-274 (1997)

  • [42]A. Jaleel, G. C. Henderson, B. J. Madden, K. A. Klaus, D. M. Morse, S. Gopala and K. S. Nair: Identification of de novo synthesized and relatively older proteins: accelerated oxidative damage to de novo synthesized apolipoprotein A-1 in type 1 diabetes. Diabetes, 59(10), 2366-2374 (2010)

  • [43]M. B. Sengupta, M. Basu, S. Iswarari, K. K. Mukhopadhyay, K. P. Sardar, B. Acharyya, P. K. Mohanty and D. Mukhopadhyay: CSF Proteomics of Secondary Phase Spinal Cord Injury in Human Subjects: Perturbed Molecular Pathways Post Injury. PLoS One, 9(10) (2014)

  • [44]R. A. Hegele: Plasma lipoproteins: genetic influences and clinical implications. Nat Rev Genet, 10(2), 109-121 (2009)

  • [45]M. J. Ladu, C. Reardon, L. Van Eldik, A. M. Fagan, G. Bu, D. Holtzman and G. S. Getz: Lipoproteins in the central nervous system. Ann N Y Acad Sci, 903, 167-175 (2000)

  • [46]A. J. Lusis: Atherosclerosis. Nature, 407 (6801), 233-241 (2000)

  • [47]A. Andreola, V. Bellotti, S. Giorgetti, P. Mangione, L. Obici, M. Stoppini, J. Torres, E. Monzani, G. Merlini and M. Sunde: Conformational switching and fibrillogenesis in the amyloidogenic fragment of apolipoprotein a-I. J Biol Chem, 278(4), 2444-2451 (2003)

  • [48]C. Yu, K. L. Youmans and M. J. LaDu: Proposed mechanism for lipoprotein remodelling in the brain. Biochim Biophys Acta, 1801(8), 819-823 (2010)

  • [49]O. Gursky: Structural stability and functional remodeling of high-density lipoproteins. FEBS Lett (2015)

  • [50]M. C. Phillips: New insights into the determination of HDL structure by apolipoproteins: Thematic review series: high density lipoprotein structure, function, and metabolism. J Lipid Res, 54(8), 2034-2048 (2013)

  • [51]M. L. Varban, F. Rinninger, N. Wang, V. Fairchild-Huntress, J. H. Dunmore, Q. Fang, M. L. Gosselin, K. L. Dixon, J. D. Deeds, S. L. Acton, A. R. Tall and D. Huszar: Targeted mutation reveals a central role for SR-BI in hepatic selective uptake of high density lipoprotein cholesterol. Proc Natl Acad Sci U S A, 95(8), 4619-4624 (1998)

  • [52]A. N. Hoofnagle and J. W. Heinecke: Lipoproteomics: using mass spectrometry-based proteomics to explore the assembly, structure, and function of lipoproteins. J Lipid Res, 50(10), 1967-1975 (2009)

  • [53]I. Bjorkhem and S. Meaney: Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol, 24(5), 806-815 (2004)

  • [54]G. J. Snipes and U. Suter: Cholesterol and myelin. Subcell Biochem, 28, 173-204 (1997)

  • [55]A. Chakrabarti, A. Chatterjee, M. B. Sengupta, P. Chattopadhyay and D. Mukhopadhyay: Altered Levels of Amyloid Precursor Protein Intracellular Domain-interacting Proteins in Alzheimer Disease. Alzheimer Disease & Associated Disorders, 28(3), 283-290 (2014)

  • [56]I. Borghini, F. Barja, D. Pometta and R. W. James: Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid. Biochim Biophys Acta, 1255(2), 192-200 (1995)

  • [57]M. J. LaDu, S. M. Gilligan, J. R. Lukens, V. G. Cabana, C. A. Reardon, L. J. Van Eldik and D. M. Holtzman: Nascent astrocyte particles differ from lipoproteins in CSF. J Neurochem, 70(5), 2070-2081 (1998)

  • [58]S. D. Harr, L. Uint, R. Hollister, B. T. Hyman and A. J. Mendez: Brain expression of apolipoproteins E, J, and A-I in Alzheimer’s disease. J Neurochem, 66(6), 2429-2435 (1996)

  • [59]D. A. Elliott, C. S. Weickert and B. Garner: Apolipoproteins in the brain: implications for neurological and psychiatric disorders. Clin Lipidol, 51(4), 555-573 (2010)

  • [60]A. Rigotti, B. Trigatti, J. Babitt, M. Penman, S. Xu and M. Krieger: Scavenger receptor BI--a cell surface receptor for high density lipoprotein. Curr Opin Lipidol, 8(3), 181-188 (1997)

  • [61]E. Favari, A. Chroni, U. J. Tietge, I. Zanotti, J. C. Escola-Gil and F. Bernini: Cholesterol efflux and reverse cholesterol transport. Handb Exp Pharmacol, 224, 181-206 (2015)

  • [62]G. J. Zhao, K. Yin, Y. C. Fu and C. K. Tang: The interaction of ApoA-I and ABCA1 triggers signal transduction pathways to mediate efflux of cellular lipids. Mol Med, 18, 149-158 (2012)

  • [63]J. R. Nofer: Signal transduction by HDL: agonists, receptors, and signaling cascades. Handb Exp Pharmacol, 224, 229-256 (2015)

  • [64]B. J. Van Lenten, S. Y. Hama, F. C. de Beer, D. M. Stafforini, T. M. McIntyre, S. M. Prescott, B. N. La Du, A. M. Fogelman and M. Navab: Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest, 96(6), 2758-2767 (1995)

  • [65]A. J. Murphy, K. J. Woollard, A. Hoang, N. Mukhamedova, R. A. Stirzaker, S. P. McCormick, A. T. Remaley, D. Sviridov and J. Chin-Dusting: High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol, 28(11), 2071-2077 (2008)

  • [66]J. R. Nofer, A. T. Remaley, R. Feuerborn, I. Wolinnska, T. Engel, A. von Eckardstein and G. Assmann: Apolipoprotein A-I activates Cdc42 signaling through the ABCA1 transporter. J Lipid Res, 47(4), 794-803 (2006)

  • [67]L. K. Curtiss, D. T. Valenta, N. J. Hime and K. A. Rye: What is so special about apolipoprotein AI in reverse cholesterol transport? Arterioscler Thromb Vasc Biol, 26(1), 12-19 (2006)

  • [68]P. S. Chetty, L. Mayne, S. Lund-Katz, D. Stranz, S. W. Englander and M. C. Phillips: Helical structure and stability in human apolipoprotein A-I by hydrogen exchange and mass spectrometry. Proc Natl Acad Sci U S A, 106(45), 19005-19010 (2009)

  • [69]M. N. Oda, T. M. Forte, R. O. Ryan and J. C. Voss: The C-terminal domain of apolipoprotein A-I contains a lipid-sensitive conformational trigger. Nat Struct Biol, 10(6), 455-460 (2003)

  • [70]I. N. Gorshkova, T. Liu, H. Y. Kan, A. Chroni, V. I. Zannis and D. Atkinson: Structure and stability of apolipoprotein a-I in solution and in discoidal high-density lipoprotein probed by double charge ablation and deletion mutation. Biochemistry, 45(4), 1242-1254 (2006)

  • [71]O. Gursky and D. Atkinson: Thermal unfolding of human high-density apolipoprotein A-1: implications for a lipid-free molten globular state. Proc Natl Acad Sci U S A, 93(7), 2991-2995 (1996)

  • [72]M. Tanaka, P. Dhanasekaran, D. Nguyen, M. Nickel, Y. Takechi, S. Lund-Katz, M. C. Phillips and H. Saito: Influence of N-terminal helix bundle stability on the lipid-binding properties of human apolipoprotein A-I. Biochim Biophys Acta, 1811(1), 25-30 (2011)

  • [73]J. B. Massey and H. J. Pownall: Cholesterol is a determinant of the structures of discoidal high density lipoproteins formed by the solubilization of phospholipid membranes by apolipoprotein A-I. Biochim Biophys Acta, 1781(5), 245-253 (2008)

  • [74]V. I. Zannis, P. Fotakis, G. Koukos, D. Kardassis, C. Ehnholm, M. Jauhiainen and A. Chroni: HDL biogenesis, remodeling, and catabolism. Handb Exp Pharmacol, 224, 53-111 (2015)

  • [75]A. Jonas: Lecithin cholesterol acyltransferase. Biochim Biophys Acta, 1529(1-3), 245-256 (2000)

  • [76]P. J. Barter, H. B. Brewer, Jr., M. J. Chapman, C. H. Hennekens, D. J. Rader and A. R. Tall: Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol, 23(2), 160-167 (2003)

  • [77]S. Lusa, M. Jauhiainen, J. Metso, P. Somerharju and C. Ehnholm: The mechanism of human plasma phospholipid transfer protein-induced enlargement of high-density lipoprotein particles: evidence for particle fusion. Biochem J, 313 (Pt 1), 275-282 (1996)

  • [78]C. Rohrl and H. Stangl: HDL endocytosis and resecretion. Biochim Biophys Acta, 1831(11), 1626-1633 (2013)

  • [79]J. M. Dietschy: Central nervous system: cholesterol turnover, brain development and neurodegeneration. Biol Chem, 390(4), 287-293 (2009)

  • [80]C. Vitali, C. L. Wellington and L. Calabresi: HDL and cholesterol handling in the brain. Cardiovasc Res, 103(3), 405-413 (2014)

  • [81]J. M. Dietschy and S. D. Turley: Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res, 45(8), 1375-1397 (2004)

  • [82]S. Koch, N. Donarski, K. Goetze, M. Kreckel, H. J. Stuerenburg, C. Buhmann and U. Beisiegel: Characterization of four lipoprotein classes in human cerebrospinal fluid. J Lipid Res, 42(7), 1143-1151 (2001)

  • [83]Z. Balazs, U. Panzenboeck, A. Hammer, A. Sovic, O. Quehenberger, E. Malle and W. Sattler: Uptake and transport of high-density lipoprotein (HDL) and HDL-associated alpha-tocopherol by an in vitro blood-brain barrier model. J Neurochem, 89(4), 939-950 (2004)

  • [84]W. S. Kim, C. S. Weickert and B. Garner: Role of ATP-binding cassette transporters in brain lipid transport and neurological disease. J Neurochem, 104(5), 1145-1166 (2008)

  • [85]R. P. Koldamova, I. M. Lefterov, M. D. Ikonomovic, J. Skoko, P. I. Lefterov, B. A. Isanski, S. T. DeKosky and J. S. Lazo: 22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion. J Biol Chem, 278(15), 13244-13256 (2003)

  • [86]D. M. Holtzman, J. Herz and G. Bu: Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med, 2(3), a006312 (2012)

  • [87]V. I. Zannis, A. Chroni and M. Krieger: Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med (Berl), 84(4), 276-294 (2006)

  • [88]V. Hirsch-Reinshagen, J. Donkin, S. Stukas, J. Chan, A. Wilkinson, J. Fan, J. S. Parks, J. A. Kuivenhoven, D. Lutjohann, H. Pritchard and C. L. Wellington: LCAT synthesized by primary astrocytes esterifies cholesterol on glia-derived lipoproteins. J Lipid Res, 50(5), 885-893 (2009)

  • [89]J. J. Albers, J. H. Tollefson, G. Wolfbauer and R. E. Albright, Jr.: Cholesteryl ester transfer protein in human brain. Int J Clin Lab Res, 21(3), 264-266 (1992)

  • [90]A. P. Chirackal Manavalan, A. Kober, J. Metso, I. Lang, T. Becker, K. Hasslitzer, M. Zandl, E. Fanaee-Danesh, J. B. Pippal, V. Sachdev, D. Kratky, J. Stefulj, M. Jauhiainen and U. Panzenboeck: Phospholipid transfer protein is expressed in cerebrovascular endothelial cells and involved in high density lipoprotein biogenesis and remodeling at the blood-brain barrier. J Biol Chem, 289(8), 4683-4698 (2014)

  • [91]S. Rossignol, M. Schwab, M. Schwartz and M. G. Fehlings: Spinal cord injury: time to move? J Neurosci, 27(44), 11782-11792 (2007)

  • [92]J. W. Heinecke: The HDL proteome: a marker--and perhaps mediator--of coronary artery disease. J Lipid Res, 50 Suppl, S167-171 (2009)

  • [93]C. Grunfeld, M. Marshall, J. K. Shigenaga, A. H. Moser, P. Tobias and K. R. Feingold: Lipoproteins inhibit macrophage activation by lipoteichoic acid. J Lipid Res, 40(2), 245-252 (1999)

  • [94]M. Wendel, R. Paul and A. R. Heller: Lipoproteins in inflammation and sepsis. II. Clinical aspects. Intensive Care Med, 33(1), 25-35 (2007)

  • [95]A. J. Wilhelm, M. Zabalawi, J. S. Owen, D. Shah, J. M. Grayson, A. S. Major, S. Bhat, D. P. Gibbs, Jr., M. J. Thomas and M. G. Sorci-Thomas: Apolipoprotein A-I modulates regulatory T cells in autoimmune LDLr-/-, ApoA-I-/-mice. J Biol Chem, 285(46), 36158-36169 (2010)

  • [96]H. Feng, L. Guo, D. Wang, H. Gao, G. Hou, Z. Zheng, J. Ai, O. Foreman, A. Daugherty and X. A. Li: Deficiency of scavenger receptor BI leads to impaired lymphocyte homeostasis and autoimmune disorders in mice. Arterioscler Thromb Vasc Biol, 31(11), 2543-2551 (2011)

  • [97]A. J. Murphy, M. Westerterp, L. Yvan-Charvet and A. R. Tall: Anti-atherogenic mechanisms of high density lipoprotein: effects on myeloid cells. Biochim Biophys Acta, 1821(3), 513-521 (2012)

  • [98]D. De Nardo, L. I. Labzin, H. Kono, R. Seki, S. V. Schmidt, M. Beyer, D. Xu, S. Zimmer, C. Lahrmann, F. A. Schildberg, J. Vogelhuber, M. Kraut, T. Ulas, A. Kerksiek, W. Krebs, N. Bode, A. Grebe, M. L. Fitzgerald, N. J. Hernandez, B. R. Williams, P. Knolle, M. Kneilling, M. Rocken, D. Lutjohann, S. D. Wright, J. L. Schultze and E. Latz: High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat Immunol, 15(2), 152-160 (2014)

  • [99]K. D. Kim, H. Y. Lim, H. G. Lee, D. Y. Yoon, Y. K. Choe, I. Choi, S. G. Paik, Y. S. Kim, Y. Yang and J. S. Lim: Apolipoprotein A-I induces IL-10 and PGE2 production in human monocytes and inhibits dendritic cell differentiation and maturation. Biochem Biophys Res Commun, 338(2), 1126-1136 (2005)

  • [100]K. Simons and E. Ikonen: Functional rafts in cell membranes. Nature, 387 (6633), 569-572 (1997)

  • [101]R. Zidovetzki and I. Levitan: Use of cyclodextrins to manipulate plasma membrane cholesterol content: evidence, misconceptions and control strategies. Biochim Biophys Acta, 1768(6), 1311-1324 (2007)

  • [102]P. S. Kabouridis and E. C. Jury: Lipid rafts and T-lymphocyte function: implications for autoimmunity. FEBS Lett, 582(27), 3711-3718 (2008)

  • [103]H. A. Anderson, E. M. Hiltbold and P. A. Roche: Concentration of MHC class II molecules in lipid rafts facilitates antigen presentation. Nat Immunol, 1(2), 156-162 (2000)

  • [104]L. E. Smythies, C. R. White, A. Maheshwari, M. N. Palgunachari, G. M. Anantharamaiah, M. Chaddha, A. R. Kurundkar and G. Datta: Apolipoprotein A-I mimetic 4F alters the function of human monocyte-derived macrophages. Am J Physiol Cell Physiol, 298(6), C1538-1548 (2010)

  • [105]X. Zhu, J. Y. Lee, J. M. Timmins, J. M. Brown, E. Boudyguina, A. Mulya, A. K. Gebre, M. C. Willingham, E. M. Hiltbold, N. Mishra, N. Maeda and J. S. Parks: Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages. J Biol Chem, 283(34), 22930-22941 (2008)

  • [106]S. H. Wang, S. G. Yuan, D. Q. Peng and S. P. Zhao: HDL and ApoA-I inhibit antigen presentation-mediated T cell activation by disrupting lipid rafts in antigen presenting cells. Atherosclerosis, 225(1), 105-114 (2012)

  • [107]A. J. Murphy, K. J. Woollard, A. Suhartoyo, R. A. Stirzaker, J. Shaw, D. Sviridov and J. P. Chin-Dusting: Neutrophil activation is attenuated by high-density lipoprotein and apolipoprotein A-I in in vitro and in vivo models of inflammation. Arterioscler Thromb Vasc Biol, 31(6), 1333-1341 (2011)

  • [108]H. J. van Leeuwen, E. C. Heezius, G. M. Dallinga, J. A. van Strijp, J. Verhoef and K. P. van Kessel: Lipoprotein metabolism in patients with severe sepsis. Crit Care Med, 31(5), 1359-1366 (2003)

  • [109]J. Y. Chien, J. S. Jerng, C. J. Yu and P. C. Yang: Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis. Crit Care Med, 33(8), 1688-1693 (2005)

  • [110]V. G. Cabana, J. N. Siegel and S. M. Sabesin: Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J Lipid Res, 30(1), 39-49 (1989)

  • [111]M. Menschikowski, A. Hagelgans and G. Siegert: Secretory phospholipase A2 of group IIA: is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases? Prostaglandins Other Lipid Mediat, 79(1-2), 1-33 (2006)

  • [112]K. O. Badellino, M. L. Wolfe, M. P. Reilly and D. J. Rader: Endothelial lipase is increased in vivo by inflammation in humans. Circulation, 117(5), 678-685 (2008)

  • [113]M. de la Llera Moya, F. C. McGillicuddy, C. C. Hinkle, M. Byrne, M. R. Joshi, V. Nguyen, J. Tabita-Martinez, M. L. Wolfe, K. Badellino, L. Pruscino, N. N. Mehta, B. F. Asztalos and M. P. Reilly: Inflammation modulates human HDL composition and function in vivo. Atherosclerosis, 222(2), 390-394 (2012)

  • [114]J. H. Graversen, G. Castro, A. Kandoussi, H. Nielsen, E. I. Christensen, A. Norden and S. K. Moestrup: A pivotal role of the human kidney in catabolism of HDL protein components apolipoprotein A-I and A-IV but not of A-II. Lipids, 43(5), 467-470 (2008)

  • [115]A. Jahangiri, M. C. de Beer, V. Noffsinger, L. R. Tannock, C. Ramaiah, N. R. Webb, D. R. van der Westhuyzen and F. C. de Beer: HDL remodeling during the acute phase response. Arterioscler Thromb Vasc Biol, 29(2), 261-267 (2009)

  • [116]G. Cavigiolio and S. Jayaraman: Proteolysis of apolipoprotein A-I by secretory phospholipase A(2): a new link between inflammation and atherosclerosis. J Biol Chem, 289(14), 10011-10023 (2014)

  • [117]N. Hyka, J. M. Dayer, C. Modoux, T. Kohno, C. K. Edwards, 3rd, P. Roux-Lombard and D. Burger: Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood, 97(8), 2381-2389 (2001)

  • [118]M. A. Navarro, R. Carpintero, S. Acin, J. M. Arbones-Mainar, L. Calleja, R. Carnicer, J. C. Surra, M. A. Guzman-Garcia, N. Gonzalez-Ramon, M. Iturralde, F. Lampreave, A. Pineiro and J. Osada: Immune-regulation of the apolipoprotein A-I/C-III/A-IV gene cluster in experimental inflammation. Cytokine, 31(1), 52-63 (2005)

  • [119]D. A. Mogilenko, E. B. Dizhe, V. S. Shavva, I. A. Lapikov, S. V. Orlov and A. P. Perevozchikov: Role of the nuclear receptors HNF4 alpha, PPAR alpha, and LXRs in the TNF alpha-mediated inhibition of human apolipoprotein A-I gene expression in HepG2 cells. Biochemistry, 48(50), 11950-11960 (2009)

  • [120]R. A. Tanhoffer, R. K. Yamazaki, E. A. Nunes, A. I. Pchevozniki, A. M. Pchevozniki, C. Nogata, J. Aikawa, S. J. Bonatto, G. Brito, M. D. Lissa and L. C. Fernandes: Glutamine concentration and immune response of spinal cord-injured rats. J Spinal Cord Med, 30(2), 140-146 (2007) injured rats. J Spinal Cord Med, 30(2), 140-146 (2007)

  • [121]N. P. Turrin and S. Rivest: Molecular and cellular immune mediators of neuroprotection. Mol Neurobiol, 34(3), 221-242 (2006)

  • [122]S. Hendrix and R. Nitsch: The role of T helper cells in neuroprotection and regeneration. J Neuroimmunol, 184(1-2), 100-112 (2007)

  • [123]W. Luu, L. J. Sharpe, I. C. Gelissen and A. J. Brown: The role of signalling in cellular cholesterol homeostasis. IUBMB Life, 65(8), 675-684 (2013)

  • [124]D. Kardassis, A. Gafencu, V. I. Zannis and A. Davalos: Regulation of HDL genes: transcriptional, posttranscriptional, and posttranslational. Handb Exp Pharmacol, 224, 113-179 (2015)

  • [125]Y. W. Hu, X. Ma, X. X. Li, X. H. Liu, J. Xiao, Z. C. Mo, J. Xiang, D. F. Liao and C. K. Tang: Eicosapentaenoic acid reduces ABCA1 serine phosphorylation and impairs ABCA1-dependent cholesterol efflux through cyclic AMP/protein kinase A signaling pathway in THP-1 macrophage-derived foam cells. Atherosclerosis, 204(2), e35-43 (2009)

  • [126]B. Haidar, M. Denis, M. Marcil, L. Krimbou and J. Genest, Jr.: Apolipoprotein A-I activates cellular cAMP signaling through the ABCA1 transporter. J Biol Chem, 279(11), 9963-9969 (2004)

  • [127]R. H. See, R. A. Caday-Malcolm, R. R. Singaraja, S. Zhou, A. Silverston, M. T. Huber, J. Moran, E. R. James, R. Janoo, J. M. Savill, V. Rigot, L. H. Zhang, M. Wang, G. Chimini, C. L. Wellington, S. R. Tafuri and M. R. Hayden: Protein kinase A site-specific phosphorylation regulates ATP-binding cassette A1 (ABCA1)-mediated phospholipid efflux. J Biol Chem, 277(44), 41835-41842 (2002)

  • [128]Y. Yamauchi, C. C. Chang, M. Hayashi, S. Abe-Dohmae, P. C. Reid, T. Y. Chang and S. Yokoyama: Intracellular cholesterol mobilization involved in the ABCA1/apolipoprotein-mediated assembly of high density lipoprotein in fibroblasts. J Lipid Res, 45(10), 1943-1951 (2004)

  • [129]Y. Yamauchi, M. Hayashi, S. Abe-Dohmae and S. Yokoyama: Apolipoprotein A-I activates protein kinase C alpha signaling to phosphorylate and stabilize ATP binding cassette transporter A1 for the high density lipoprotein assembly. J Biol Chem, 278(48), 47890-47897 (2003)

  • [130]R. S. Kiss, J. Maric and Y. L. Marcel: Lipid efflux in human and mouse macrophagic cells: evidence for differential regulation of phospholipid and cholesterol efflux. J Lipid Res, 46(9), 1877-1887 (2005)

  • [131]Y. Wang and J. F. Oram: Unsaturated fatty acids phosphorylate and destabilize ABCA1 through a protein kinase C delta pathway. J Lipid Res, 48(5), 1062-1068 (2007)

  • [132]C. Tang, A. M. Vaughan, G. M. Anantharamaiah and J. F. Oram: Janus kinase 2 modulates the lipid-removing but not protein-stabilizing interactions of amphipathic helices with ABCA1. J Lipid Res, 47(1), 107-114 (2006)

  • [133]C. Tang, Y. Liu, P. S. Kessler, A. M. Vaughan and J. F. Oram: The macrophage cholesterol exporter ABCA1 functions as an anti-inflammatory receptor. J Biol Chem, 284(47), 32336-32343 (2009)

  • [134]L. M. Williams, U. Sarma, K. Willets, T. Smallie, F. Brennan and B. M. Foxwell: Expression of constitutively active STAT3 can replicate the cytokine-suppressive activity of interleukin-10 in human primary macrophages. J Biol Chem, 282(10), 6965-6975 (2007)

  • [135]P. J. Murray: Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response. Curr Opin Pharmacol, 6(4), 379-386 (2006)

  • [136]X. Zhou, Z. Yin, X. Guo, D. P. Hajjar and J. Han: Inhibition of ERK1/2 and activation of liver X receptor synergistically induce macrophage ABCA1 expression and cholesterol efflux. J Biol Chem, 285(9), 6316-6326 (2010)

  • [137]J. R. Nofer, R. Feuerborn, B. Levkau, A. Sokoll, U. Seedorf and G. Assmann: Involvement of Cdc42 signaling in apoA-I-induced cholesterol efflux. J Biol Chem, 278(52), 53055-53062 (2003)

  • [138]D. Gonsalvez, A. H. Ferner, H. Peckham, S. S. Murray and J. Xiao: The roles of extracellular related-kinases 1 and 2 signaling in CNS myelination. Neuropharmacology (2015)

  • [139]S. L. Fyffe-Maricich, A. Schott, M. Karl, J. Krasno and R. H. Miller: Signaling through ERK1/2 controls myelin thickness during myelin repair in the adult central nervous system. J Neurosci, 33(47), 18402-18408 (2013)

  • [140]D. Liu, L. Ji, X. Tong, B. Pan, J. Y. Han, Y. Huang, Y. E. Chen, S. Pennathur, Y. Zhang and L. Zheng: Human apolipoprotein A-I induces cyclooxygenase-2 expression and prostaglandin I-2 release in endothelial cells through ATP-binding cassette transporter A1. Am J Physiol Cell Physiol, 301(3), C739-748 (2013)

  • [141]J. Karwatsky, L. Ma, F. Dong and X. Zha: Cholesterol efflux to apoA-I in ABCA1-expressing cells is regulated by Ca2+-dependent calcineurin signaling. J Lipid Res, 51(5), 1144-1156 (2010)

  • [142]N. Iwamoto, R. Lu, N. Tanaka, S. Abe-Dohmae and S. Yokoyama: Calmodulin interacts with ATP binding cassette transporter A1 to protect from calpain-mediated degradation and upregulates high-density lipoprotein generation. Arterioscler Thromb Vasc Biol, 30(7), 1446-1452 (2010)

  • [143]Y. Takahashi and J. D. Smith: Cholesterol efflux to apolipoprotein AI involves endocytosis and resecretion in a calcium-dependent pathway. Proc Natl Acad Sci U S A, 96(20), 11358-11363 (1999)

  • [144]V. Mulay, P. Wood, C. Rentero, C. Enrich and T. Grewal: Signal transduction pathways provide opportunities to enhance HDL and apoAI-dependent reverse cholesterol transport. Curr Pharm Biotechnol, 13(2), 352-364 (2012)

  • [145]Y. Takai, T. Sasaki and T. Matozaki: Small GTP-binding proteins. Physiol Rev, 81(1), 153-208 (2001)

  • [146]K. Hirano, F. Matsuura, K. Tsukamoto, Z. Zhang, A. Matsuyama, K. Takaishi, R. Komuro, T. Suehiro, S. Yamashita, Y. Takai and Y. Matsuzawa: Decreased expression of a member of the Rho GTPase family, Cdc42Hs, in cells from Tangier disease -the small G protein may play a role in cholesterol efflux. FEBS Lett, 484(3), 275-279 (2000)

  • [147]K. Tsukamoto, K. Hirano, S. Yamashita, N. Sakai, C. Ikegami, Z. Zhang, F. Matsuura, H. Hiraoka, A. Matsuyama, M. Ishigami and Y. Matsuzawa: Retarded intracellular lipid transport associated with reduced expression of Cdc42, a member of Rho-GTPases, in human aged skin fibroblasts: a possible function of Cdc42 in mediating intracellular lipid transport. Arterioscler Thromb Vasc Biol, 22(11), 1899-1904 (2002)

  • [148]V. Pernet and M. E. Schwab: The role of Nogo-A in axonal plasticity, regrowth and repair. Cell Tissue Res, 349(1), 97-104 (2012)

  • [149]M. E. Schwab: Nogo and axon regeneration. Curr Opin Neurobiol, 14(1), 118-124 (2004)

  • [150]J. Silver, M. E. Schwab and P. G. Popovich: Central nervous system regenerative failure: role of oligodendrocytes, astrocytes, and microglia. Cold Spring Harb Perspect Biol, 7(3), a020602 (2014)

  • [151]Y. Ohtake and S. Li: Molecular mechanisms of scar-sourced axon growth inhibitors. Brain Res (2014)

  • [152]J. M. Cregg, M. A. DePaul, A. R. Filous, B. T. Lang, A. Tran and J. Silver: Functional regeneration beyond the glial scar. Exp Neurol, 253, 197-207 (2014)

  • [153]S. C. Gordts, I. Muthuramu, R. Amin, F. Jacobs and B. De Geest: The Impact of Lipoproteins on Wound Healing: Topical HDL Therapy Corrects Delayed Wound Healing in Apolipoprotein E Deficient Mice. Pharmaceuticals (Basel), 7(4), 419-432 (2014)

  • [154]A. M. Fagan, G. Bu, Y. Sun, A. Daugherty and D. M. Holtzman: Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein. J Biol Chem, 271(47), 30121-30125 (1996)

  • [155]A. E. Roher, C. L. Maarouf, L. I. Sue, Y. Hu, J. Wilson and T. G. Beach: Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer’s disease. Biomarkers, 14(7), 493-501 (2009)

  • [156]J. T. Huang, L. Wang, S. Prabakaran, M. Wengenroth, H. E. Lockstone, D. Koethe, C. W. Gerth, S. Gross, D. Schreiber, K. Lilley, M. Wayland, D. Oxley, F. M. Leweke and S. Bahn: Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues. Mol Psychiatry, 13(12), 1118-1128 (2008)

  • [157]A. Pirillo, A. L. Catapano and G. D. Norata: HDL in infectious diseases and sepsis. Handb Exp Pharmacol, 224, 483-508 (2015)

  • [158]N. A. Ramella, O. J. Rimoldi, E. D. Prieto, G. R. Schinella, S. A. Sanchez, M. S. Jaureguiberry, M. E. Vela, S. T. Ferreira and M. A. Tricerri: Human apolipoprotein A-I-derived amyloid: its association with atherosclerosis. PLoS One, 6(7), e22532 (2011)

  • [159]A. J. Murphy, D. Dragoljevic and A. R. Tall: Cholesterol efflux pathways regulate myelopoiesis: a potential link to altered macrophage function in atherosclerosis. Front Immunol, 5, 490 (2014)

  • [160]W. Annema, A. von Eckardstein and P. T. Kovanen: HDL and atherothrombotic vascular disease. Handb Exp Pharmacol, 224, 369-403 (2015)

  • [161]Y. Uehara and K. Saku: High-density lipoprotein and atherosclerosis: Roles of lipid transporters. World J Cardiol, 6(10), 1049-1059 (2014)

  • [162]D. J. Rader and G. K. Hovingh: HDL and cardiovascular disease. Lancet, 384 (9943), 618-625 (2014)

  • [163]A. Pirillo, G. Tibolla, G. D. Norata and A. L. Catapano: HDL: to treat or not to treat? Curr Atheroscler Rep, 16(8), 429 (2014)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jun 2016Review

Possible role of apolipoprotein A1 in healing and cell death after neuronal injury

Mohor B. Sengupta 1, Debashis Mukhopadhyay 1,*
Affiliation
Article Info

1 Biophysics and Structural Genomics Division, Saha Institute of Nuclear Physics, 1/AF, Bidhannagar, Kolkata 700064, West Bengal, India

*Author to whom correspondence should be addressed.

 

Abstract

Limited axonal regeneration after traumatic injuries to the CNS presents a challenge in neuroscience. Investigation of CSF from subjects with spinal cord injury (SCI) has found that the lipid catabolism pathway is implicated in the post injury scenario. Sequestration of the CNS by the blood brain barrier ensures a mechanism of cholesterol metabolism and recycling distinct from that in the peripheral tissues. Apolipoprotein A1, the protein component of high density lipoprotein (HDL), is an abundant protein in the mammalian cerebrospinal fluid. Interaction of ApoA1 with its cellular receptor, ABCA1, gives rise to several signaling events, such as the activation of Cdc42 protein leading to actin polymerisation. Emerging evidences suggest that ApoA1 mediates anti-inflammatory effects and conversely, is negatively regulated by inflammatory cytokines. Collating these findings, added to the clinical evidences of using HDL as a therapeutic target for cardio vascular diseases, we hypothesize that ApoA1 could be useful in neurite outgrowth after mechanical injury by 1) mediating polymerisation of actin and 2) restricting inflammatory responses after injury which are deleterious to healing.

Keywords

  • Apolipoprotein
  • Inflammation
  • Neuronal Injury
  • Regeneration
  • Review

References